Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 17 of 17 publications.

Tormos A, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia Esteban R, Plana E, Farsani SF, Perez-Gutthann S, Pladevall-Vila M, Rebordosa C. Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D). Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687

Rebordosa C, Farkas DK, Montonen J, Laugesen K, Voss F, Aguado J, Bothner U, Rothman KJ, Zint K, Mines DI, Ehrenstein V. Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):827-39. doi: 10.1002/pds.5432

Arana A, Margulis AV, Varas-Lorenzo C, Bui CL, Gilsenan A, McQuay LJ, Reynolds M, Rebordosa C, Franks B, de Vogel S, Appenteng K, Perez-Gutthann S. Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150

Rebordosa C, Houben E, Laugesen K, Asmar J, Montonen JT, Aguado J, Overbeek J, Ehrenstein V, Wallace L, Gilsenan A. Utilization of olodaterol and indacaterol in Europe. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1128. doi: 10.1002/pds.4864

Plana E, Rivero-Ferrer E, Aguado J, Saigi-Morgui N, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rebordosa C. Hospitalization for heart failure among patients using aclidinium bromide and other COPD medications: a post-authorisation safety study in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1153. doi: 10.1002/pds.4864

Saigi N, Rebordosa C, Bui C, Aguado J, Plana E, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rivero-Ferrer E. A validation exercise: identifying hospitalizations for heart failure among patients with COPD in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):334. doi: 10.1002/pds.4864

Rebordosa C, Plana E, Aguado J, Thomas S, Garcia-Gil E, Perez-Gutthann S, Castellsague J. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):126-33. doi: 10.1002/pds.4448

Tormos A, Rebordosa C, Thomas S, Plana E, Rasouliyan L, Pladevall-Vila M, Fazeli-Farsani S, Deruaz-Luyet A, Brodovicz KG, Perez-Gutthann S. Time between laboratory tests and acute liver and kidney injury diagnosis codes in CPRD: are we doing it right? Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):452. doi: 10.1002/pds.4629

Aguado J, Plana E, Saigi N, Garcia-Gil E, Castellsague J, Perez-Gutthann S, Rebordosa C. The missing puff: results of multiple imputation of ppFEV1 in CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):211-2. doi: 10.1002/pds.4629

Plana E, Rebordosa C, Aguado J, Saigi N, Garcia-Gill E, Castellsague J, Perez-Gutthann S. To pile or not to pile: how to define episodes of use of COPD medications in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):123. doi: 10.1002/pds.4629

Rivero-Ferrer E, Castellsague J, Aguado J, Plana E, Saigi N, Garcia-Gil E, Perez-Gutthann S, Rebordosa C. Are you really dead? Validation of death and date of death in patients with COPD in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):122-3. doi: 10.1002/pds.4629

Rebordosa C, Castellsague J, Kristiansen N, Pottegard A, Plana E, Aguado J, Garcia-Gil E, Hallas J, Perez-Gutthann S. Severity of COPD in new users of aclidinium bromide and other COPD medications: a population-based study in the United Kingdom and Denmark. Presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):45-6. doi: 10.1002/pds

Plana E, Rebordosa C, Aguado J, Thomas S, Garcia-Gil E, Perez-Gutthann S, Castellsague J. Assessment of COPD severity in the UK CPRD. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):576. doi: 10.1002/pds

Margulis AV, Varas-Lorenzo C, Bui CL, McQuay LJ, Ziemiecki R, Reynolds M, Rebordosa C, Pladevall-Vila M, Fortuny J, Rivero-Ferrer E, Plana E, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS). Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.

McGrath LJ, Rulgomez A, Plana E, Fortuny J, Garcia-Rodriguez L, Rebordosa C, Varas-Lorenzo C, Ziemiecki R, Gilsenan AW, Andrews E. Characteristics of patients prescribed prucalopride versus an active comparator in England, Wales, and Northern Ireland. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):634.

Rebordosa C, Varas-Lorenzo C, Castellsague J, Plana E, Bui C, Aguado J, Garcia Gil E, Perez-Gutthann S. Characteristics of new users of aclidinium bromide in the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):677. doi: 10.1002/pds.4070

Plana E, McGrath LJ, Fortuny J, Ruigomez A, Fernandez-Cantero O, Garcia-Rodriguez LA, Gilsenan AW, Andrews E, Rebordosa C, Ziemiecki R. An algorithm to identify duplicate patients when pooling aggregate data from two primary care databases in the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58-9. doi: 10.1002/pds